Skip to content


Erleada (apalutamide) is a small molecule pharmaceutical. Apalutamide was first approved as Erleada on 2018-02-14. It has been approved in Europe to treat prostatic neoplasms. The pharmaceutical is active against androgen receptor. Erleada's patents are valid until 2038-04-30 (FDA).
Trade Name Erleada
Common Name Apalutamide
Indication prostatic neoplasms
Drug Class Non-steroid antiandrogens
Get full access now